Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor

A compound of formula (I),

• or a therapeutically suitable salt or prodrug thereof, wherein
• A is selected from the group consisting of —C(O)—, —S(O)—, —S(O)2—, —C(═NRa)— and —C(═S)—;
• B is selected from the group consisting of alkylene, alkenyl, carbonylalkyl, cycloalkyl, —NRb— and —NRb-alkyl;
• D is a bond or is selected from the group consisting of alkylene, aryl, arylalkyl, heterocycle and heterocyclealkyl;
• E is selected from the group consisting of alkyl, alkyl-C(O)—, alkyl-C(O)—NH—, alkyl-NH—, alkyl-NH—C(O)—, alkyl-NH—S(O)2—, alkoxy, alkyl-S—, alkyl-S(O)2—, alkyl-S(O)2—NH—, aryl, aryl-C(O)—, aryl-C(O)—NH—, aryl-C═N—O—, aryl-NH—, aryl-NH—C(O)—, aryl-NH—S(O)2—, aryloxy, aryl-S—, aryl-S-alkyl-C(O)—, aryl-S(O)2—, aryl-S(O)2—NH—, arylalkyl-C(O)—, arylalkyl-C(O)—NH—, arylalkyl-NH—, arylalkyl-NH—C(O)—, arylalkyl-NH—S(O)2—, arylalkoxy, arylalkyl-S—, arylalkyl-S(O)2—, arylalkyl-S(O)2—NH—, cycloalkyl, cycloalkyl-C(O)—, cycloalkyl-C(O)—NH—, cycloalkyl-NH—, cycloalkyl-NH—C(O)—, cycloalkyl-NH—S(O)2—, cycloalkoxy, cycloalkyl-S—, cycloalkyl-S(O)2—, cycloalkyl-S(O)2—NH—, cycloalkenyl, cycloalkenylalkyl, cycloalkenyl-C(O)—, cycloalkenyl-C(O)—NH—, cycloalkenyl-NH—, cycloalkenyl-NH—C(O)—, cycloalkenyl-NH—S(O)2—, cycloalkenyloxy, cycloalkenyl-S—, cycloalkenyl-S(O)2—, cycloalkenyl-S(O)2—NH—, heterocycle, heterocycle-C(O)—, heterocycle-C(O)—NH—, heterocycle-NH—, heterocycle-NH—C(O)—, heterocycle-NH—S(O)2—, heterocycle-O—, heterocycle-S—, heterocycle-S(O)2—, heterocycle-S(O)2—NH—, heterocyclealkyl-C(O)—, heterocyclealkyl-C(O)—NH—, heterocyclealkyl-NH—, heterocyclealkyl-NH—C(O)—, heterocyclealkyl-NH—S(O)2—, heterocyclealkyl-O—, heterocyclealkyl-S—, heterocyclealkyl-S(O)2— and heterocyclealkyl-S(O)2—NH—,
• R1 is selected from the group consisting of hydrogen and alkyl;
• R2 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy;
• R3 is RcRdN—;
• R4 is selected from the group consisting of hydrogen and alkyl, or R4 and Rc taken together with any intervening atoms form a heterocycle;
• each occurrence of R5 is independently selected from the group consisting of hydrogen and alkyl;
• Ra is selected from the group consisting of hydrogen and alkyl;
• Rb is selected from the group consisting of hydrogen and alkyl, or Rb and R1 taken together with any intervening atoms form a heterocycle;
• Rc and Rd are each independently selected from the group consisting of hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkenylalkyl, heterocycle, heterocyclealkyl and hydroxyalkyl, or Rc and Rd taken together with any intervening atoms form a heterocycle;
• Z is selected from the group consisting of hydrogen, alkyl and halogen;
• and
• m is 1, 2 or 3;
• provided that:
• if B is NRb- or NRb-alkyl, then
• D is selected from the group consisting of alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl;
• and if A is C(O), B is NRb, D is aryl, m=1, Z is H, R1 is H, R4 is H, R2 is H, and Rc and Rd are alkyl, then E cannot be heteroaryl-O.